ES2635016T3 - Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas - Google Patents

Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas Download PDF

Info

Publication number
ES2635016T3
ES2635016T3 ES14707155.9T ES14707155T ES2635016T3 ES 2635016 T3 ES2635016 T3 ES 2635016T3 ES 14707155 T ES14707155 T ES 14707155T ES 2635016 T3 ES2635016 T3 ES 2635016T3
Authority
ES
Spain
Prior art keywords
formula
mmol
compound
give
concentrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14707155.9T
Other languages
English (en)
Spanish (es)
Inventor
María del Mar Cuadrado Tejedor
Rafael FRANCO FERNÁNDEZ
Ana María García Osta
Julen Oyarzabal Santamarina
Maria Obdulia Rabal Gracia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Medica Aplicada
Original Assignee
Fundacion para la Investigacion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion para la Investigacion Medica Aplicada filed Critical Fundacion para la Investigacion Medica Aplicada
Application granted granted Critical
Publication of ES2635016T3 publication Critical patent/ES2635016T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ES14707155.9T 2013-03-01 2014-02-27 Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas Active ES2635016T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382065 2013-03-01
EP13382065 2013-03-01
PCT/EP2014/053877 WO2014131855A1 (en) 2013-03-01 2014-02-27 Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases

Publications (1)

Publication Number Publication Date
ES2635016T3 true ES2635016T3 (es) 2017-10-02

Family

ID=47901928

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14707155.9T Active ES2635016T3 (es) 2013-03-01 2014-02-27 Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas

Country Status (7)

Country Link
US (1) US9573956B2 (enExample)
EP (1) EP2961741B1 (enExample)
JP (1) JP6338601B2 (enExample)
CA (1) CA2908482A1 (enExample)
DK (1) DK2961741T3 (enExample)
ES (1) ES2635016T3 (enExample)
WO (1) WO2014131855A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505767B2 (en) * 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
EP3085700B1 (en) * 2013-12-20 2018-10-31 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Novel piperidine carboxamide compound, preparation method, and usage thereof
CA2987978C (en) * 2014-06-16 2022-08-16 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
JP2017523204A (ja) * 2014-08-04 2017-08-17 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知向上のために用いる新規化合物
WO2016120432A1 (en) * 2015-01-30 2016-08-04 Fundación Para La Investigación Médica Aplicada Compounds and methods for anticoagulation therapy
CN104610166B (zh) * 2015-03-10 2017-06-13 山东大学 嘧啶苄基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
HK1249104A1 (zh) 2015-03-13 2018-10-26 Forma Therapeutics, Inc. 作为HDAC8抑制剂的α-肉桂酰胺化合物和组合物
KR102457316B1 (ko) * 2015-06-26 2022-10-20 총킹 디캉 에릴 파마 씨오. 엘티디. 새로운 5형포스포디에스테라아제 억제제 및 그 용도
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
CN107163052B (zh) * 2017-04-18 2020-08-11 华南农业大学 一种针对多种pde-5抑制剂药物的免疫检测方法
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
CN108912029B (zh) * 2017-08-25 2021-10-01 广东东阳光药业有限公司 含氮杂环酰胺衍生物及其用途
KR102794907B1 (ko) 2017-11-27 2025-04-14 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
CN110054625B (zh) * 2018-01-18 2022-01-07 山东大学 N-酰基苯磺酰胺异羟肟酸类Bcl-2、HDAC双靶点抑制剂及制备方法和应用
CN108558890A (zh) * 2018-06-28 2018-09-21 重庆康刻尔制药有限公司 一种西地那非中间体合成方法
CN109824516B (zh) * 2019-03-14 2021-07-23 泰州精英化成医药科技有限公司 一种反式-4-羟基环已烷甲酸叔丁酯的制备方法
CN109810108B (zh) * 2019-03-20 2021-08-06 华东理工大学 2,8-二氮杂-螺-[4,5]-癸烷类嘧啶-异羟肟酸化合物及其用途
US11787812B2 (en) 2020-12-11 2023-10-17 Ildong Pharmaceutical Co., Ltd. Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors
KR20240124952A (ko) 2021-12-22 2024-08-19 어거스틴 테라퓨틱스 Hdac6 억제제로서의 화합물 및 이의 용도
CN115417877B (zh) * 2022-09-20 2024-05-14 杭州师范大学 组蛋白去乙酰化酶抑制剂及其制备和在制备抗癌症药物上的应用
CN116375714A (zh) * 2023-03-24 2023-07-04 苏州满元生物科技有限公司 卡巴地那非类药物关键中间体的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210447B2 (en) * 2002-01-04 2008-02-07 Henry Ford Health System Nitric oxide donors for treatment of disease and injury
CN1548438A (zh) * 2003-05-16 2004-11-24 烟台开发区北方药物研究所 2-取代苯基-6,8-二烃基-3H-咪唑[1,5α][1,3,5]三嗪-4-酮衍生物,其制备方法及其药物用途
DE602005017135D1 (de) * 2004-03-05 2009-11-26 Nycomed Gmbh Neue verwendung von pde5-hemmern
CA2661483A1 (en) * 2006-08-24 2008-02-28 Surface Logix, Inc. Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP2010527928A (ja) * 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
NZ603725A (en) * 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
EP2535049A1 (en) * 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil for the treatment of dementia

Also Published As

Publication number Publication date
WO2014131855A1 (en) 2014-09-04
EP2961741A1 (en) 2016-01-06
EP2961741B1 (en) 2017-04-05
US20160002246A1 (en) 2016-01-07
WO2014131855A9 (en) 2014-11-13
JP6338601B2 (ja) 2018-06-06
JP2016513130A (ja) 2016-05-12
CA2908482A1 (en) 2014-09-04
DK2961741T3 (en) 2017-07-03
US9573956B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
ES2635016T3 (es) Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
ES2963417T3 (es) Derivados de imidazol condensados como moduladores de IL-17
US9969744B2 (en) Compounds for use in cognition improvement
US8835441B2 (en) Heterobicyclic metalloprotease inhibitors
US20080161300A1 (en) Heterobicyclic metalloprotease inhibitors
CN115087440A (zh) Trpml调节剂
JP2022539538A (ja) Ｉｌ－１７調節剤としての縮合イミダゾール誘導体
US20080021024A1 (en) Metalloprotease inhibitors
NZ734768A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
AU2007321924A1 (en) Heterobicyclic metalloprotease inhibitors
AU2017319430A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
BR112020014516A2 (pt) Aminopirrolotriazinas como inibidores de quinase
JP6229717B2 (ja) ガンマセクレターゼモジュレーターとしての縮合トリアゾール誘導体
CN108137608B (zh) Janus激酶1选择性抑制剂及其药物用途
US20180215770A1 (en) Imidazo-oxadiazole and imidazo-thiadiazole derivatives
CA3141524A1 (en) Antimalarial hexahydropyrimidine analogues
NZ516363A (en) Tricyclic compounds having spiro union having FXa inhibitory activity
CA3210102A1 (en) Diazepine derivatives useful in the treatment of clostridium difficile
HK1236034B (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases